retatrutide parkinson's 🎙️ NEW EPISODE: Retatrutide—The Triple Agonist *Not licensed* Will this replace the current GLP-1 in the market. This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in weight loss trials, outperforming current Retatrutide (LY3437943) | GCGR/GIPR/GLP-1R Agonist

Solid for what it is, but it's not designed to touch hot flashes, joint discomfort, or the metabolic changes that come with menopause

DIM (diindolylmethane) DIM is used to stimulate 2 hydroxylation (neutral estrogen pathway) via CYP1A1 and reduce expression of 16 hydroxylation (potential harmful estrogen pathway) through inhibiting CYP3a4

Crippin JS (1993)

W., Howden, M

Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery